Navigation Links
$9.1 million grant to improve drug therapy using gene profiles
Date:9/8/2010

COLUMBUS, Ohio The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

The grant also funds Ohio State as a member of a nationwide Pharmacogenomics Research Network (PGRN), which connects 14 major centers across the United States with diverse specializations, working jointly to achieve this goal.

"It's estimated that 30 percent to 70 percent of people who take medication do not respond favorably and even have serious adverse reactions to it," says study leader Wolfgang Sadee, chair and professor of pharmacology, of pharmacy, of internal medicine, of psychiatry and of public health at The Ohio State University. Sadee also chairs Ohio State's Program in Pharmacogenomics.

Sadee notes that adverse drug reactions are a major cause of death and hospitalization in the United States. "We want to improve our ability to give the right drug to the right patient at the right time at the right dosage," adds Sadee.

"Because people are genetically different, they respond differently to medication," he says. "If we can identify these genetic differences, then we can prevent adverse drug reactions and predict which drugs will offer the best treatment for individual patients."

But critical genetic differences among individuals largely remain unknown, Sadee says. "Our project uses a novel approach to finding these critical genetic differences and testing them immediately in clinical trials that are under way here at Ohio State and across the world." The project will also support large-scale DNA sequencing using the latest technologies, enabling researchers to study the entire human genome.

The study led by Sadee targets genes that are important for major diseases such as central nervous system disorders, cardiovascular disease, cancer, and their therapies. It further includes new projects driven by a clinical need, such as nephritic syndrome in children to understand why some children do not respond to standard therapy.

The project involves collaborations with researchers at The Ohio State University Dorothy Davis Heart and Lung Research Institute, Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Nationwide Children's Hospital in Columbus, and at medical centers in the US, Canada, and Europe.

Ohio State's pharmacogenomics program, directed by Sadee, studies genetic factors that determine the activity of drug receptors and metabolizing enzymes, critical elements in a patient's response to most drugs in current use. The research is designed to identify clinically useful biomarkers that will help identify people who, because of their genetic make-up, respond to or metabolize drugs in ways that alter the drug's activity in the body, according to Sadee, a specialist in pharmacogenomics, a field that investigates the genetic basis for variations in drug response.

Some people, for example, may be genetically predisposed to respond to a particular drug to an unusual high degree. Such individuals would need a lower-than-usual dose of drug to avoid serious side effects. Other people may have genes that reduce drug response and may need a higher-than-usual dose to benefit from the drug. And some people may lack an enzyme entirely that is needed to metabolize a particular drug. These individuals are potentially at risk and should receive a different agent altogether.

"We are applying genome sequencing and other fundamentally new approaches to identify biomarkers that will make drugs more efficient and prevent side effects," Sadee says. The Sadee group has already identified a series of clinically promising pharmacogenetic biomarkers as potential guides in a person's therapy.

The 14 research groups within the PGRN are studying the effects of genes on people's responses to a wide variety of medicines. Each group is independently funded by the National Institute of General Medical Sciences and multiple other institutes of the NIH, and focuses on a particular area of pharmacogenomics.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related biology news :

1. UCSF receives $15 million to advance personalized medicine
2. UT Health Science Center San Antonio lands $11.6 million to study cardiac proteins
3. University of Arizona-led group awarded $9.9 million to develop super rice
4. Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out
5. Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets
6. IU physics facility awarded $5 million for cooperative neutron research
7. $7 million grant designates Nationwide Childrens as Wellstone Center
8. New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago
9. Fossil reveals 48-million-year history of zombie ants
10. University of Maryland School of Medicine receives $7.9 million grant for super research magnet
11. Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... 23, 2016 Cercacor today introduced Ember TM ... trainers non-invasively measure hemoglobin, Oxygen Content, Oxygen ... Respiration Rate in approximately 30 seconds. Smaller than a ... immediate access to key data about their bodies to ... regimen. Hemoglobin carries oxygen to muscles. ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA is ... cart. The new website has been designed to provide the best user-friendly experience ... to access detailed product information, read educational industry content as well as share ...
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... results for the fourth quarter and fiscal year ended September 30, ... , , ... -based life sciences and diagnostics company that develops and commercializes ... Commercial Highlights Achieved revenues of $1.4 million more ...
(Date:12/6/2016)... ... December 06, 2016 , ... Superior Controls, Inc ... today announced the company has successfully completed its 50th consecutive audit. For ... systems integration services to leading companies in life sciences, food and beverage, energy ...
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
Breaking Biology Technology: